JP2011500073A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500073A5
JP2011500073A5 JP2010530432A JP2010530432A JP2011500073A5 JP 2011500073 A5 JP2011500073 A5 JP 2011500073A5 JP 2010530432 A JP2010530432 A JP 2010530432A JP 2010530432 A JP2010530432 A JP 2010530432A JP 2011500073 A5 JP2011500073 A5 JP 2011500073A5
Authority
JP
Japan
Prior art keywords
protein
seq
subunit
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500073A (ja
JP5314033B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/064224 external-priority patent/WO2009053368A1/en
Publication of JP2011500073A publication Critical patent/JP2011500073A/ja
Publication of JP2011500073A5 publication Critical patent/JP2011500073A5/ja
Application granted granted Critical
Publication of JP5314033B2 publication Critical patent/JP5314033B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530432A 2007-10-22 2008-10-21 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ Expired - Fee Related JP5314033B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07118980.7 2007-10-22
EP07118980 2007-10-22
US714207P 2007-12-11 2007-12-11
US61/007,142 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (3)

Publication Number Publication Date
JP2011500073A JP2011500073A (ja) 2011-01-06
JP2011500073A5 true JP2011500073A5 (OSRAM) 2011-12-08
JP5314033B2 JP5314033B2 (ja) 2013-10-16

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530432A Expired - Fee Related JP5314033B2 (ja) 2007-10-22 2008-10-21 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ

Country Status (6)

Country Link
EP (1) EP2203180B1 (OSRAM)
JP (1) JP5314033B2 (OSRAM)
AU (1) AU2008314697B2 (OSRAM)
ES (1) ES2400107T3 (OSRAM)
IL (1) IL204948A (OSRAM)
WO (1) WO2009053368A1 (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534399A (en) 2002-01-25 2008-08-29 G2 Therapies Ltd Monoclonal antibodies against extracellular loops of C5aR
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
ES2562627T3 (es) 2008-02-20 2016-03-07 Novo Nordisk A/S Anticuerpos anti-C5aR humanizados
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2409990A4 (en) 2009-03-19 2013-01-23 Chugai Pharmaceutical Co Ltd VARIANT OF A CONSTANT ANTIBODY REGION
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP2013519699A (ja) * 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
WO2011108714A1 (ja) * 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
DK2591006T3 (da) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
EP4279513A3 (en) * 2010-11-30 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
JP6141834B2 (ja) * 2011-06-06 2017-06-07 ノヴォ ノルディスク アー／エス 治療抗体
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2943943C (en) 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
BR112016026299A2 (pt) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
LT3221346T (lt) 2014-11-21 2020-11-10 Bristol-Myers Squibb Company Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
PL3380522T3 (pl) 2015-11-25 2024-03-25 Visterra, Inc. Cząsteczki przeciwciał wobec april i ich zastosowania
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
AU2016381964B2 (en) * 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
US20220041719A1 (en) * 2018-12-05 2022-02-10 Morphosys Ag Multispecific antigen-binding molecules
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006077266A1 (en) * 2005-01-24 2006-07-27 Laboratoires Serono S.A. Use of soluble cd164 variants in inflammatory and/or autoimmune disorders
JP2008545409A (ja) * 2005-05-26 2008-12-18 シェーリング コーポレイション インターフェロン−ＩｇＧ融合体

Similar Documents

Publication Publication Date Title
JP2011500073A5 (OSRAM)
Thye et al. Emerging SARS-CoV-2 variants of concern (VOCs): an impending global crisis
Tang et al. Molecular medical microbiology
JP2012136541A5 (OSRAM)
JP2012126742A5 (OSRAM)
JP2011528896A5 (OSRAM)
JP2012095652A5 (OSRAM)
JP2010011868A5 (OSRAM)
JP2010166916A5 (OSRAM)
JP2011528222A5 (OSRAM)
JP2016512425A5 (OSRAM)
JP2012001560A5 (OSRAM)
Villena et al. Lactiplantibacillus plantarum as a potential adjuvant and delivery system for the development of SARS-CoV-2 oral vaccines
JP2014042533A5 (OSRAM)
JP2012524733A5 (OSRAM)
JP2013520176A5 (OSRAM)
JP2010166921A5 (OSRAM)
JP2015523328A5 (OSRAM)
JP2013507907A5 (OSRAM)
HRP20170193T4 (hr) Izolirani polipeptid iz proteina toksina a i toksina b iz c.difficile i njegove uporabe
JP2006149406A5 (OSRAM)
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
JP2010532656A5 (OSRAM)
JP2011528897A5 (OSRAM)
JP2009515831A5 (OSRAM)